ClinicalTrials.gg
RecruitingNCT04923191PIONEER-IVUpdated Oct 30, 2023

The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent

An interventional study of Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care in Coronary Artery Disease, sponsored by National University of Ireland, Galway, Ireland. Recruiting at 19 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-30.

Sponsored by National University of Ireland, Galway, Ireland · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,540
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Coronary Artery Disease with a site in Netherlands — 44 open to participants now, 66 under way, 5 of them phase 3. Coronary Artery Disease · Netherlands.

Planned enrollment
26th of 198
2,540 · median 348
Started
2021
with 17 others
No phase
109 of 283
19 open now
Primary completion
2026-01
later than 22 of 65 live
Registered
225th of 283
by date

Among the 283 studies in Coronary Artery Disease with a site in Netherlands, this one is the 26th largest by planned enrollment of the 198 interventional ones that give a count, is one of 18 that started in 2021, is one of 109 with no phase, reaches primary completion later than 22 of the 65 other live ones, and was the 225th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

44 of the 283 studies in Coronary Artery Disease with a site in Netherlands are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Coronary Artery Disease with a site in Netherlands, or all of them as a file.
02

Study summary

PIONEER-IV is a prospective, single-blind (patient), randomized, 1:1, controlled, multi-center study comparing clinical outcomes between angiography-derived physiology guidance to LRDP and usual care in an all-comers patient population (including patients with high bleeding risk, HBR) undergoing PCI with unrestrictive use of the HT Supreme sirolimus-eluting stent. Patients will be randomized to either angio-based physiology guidance angio-FFR (Quantitative Flow Ratio and coronary angiography-derived FFR, caFFR) or local routine diagnostic procedure (LRDP) and usual care. Patients will be treated with 1-year P2Y12 inhibitor monotherapy after 1-month of dual-antiplatelet therapy in approximately 2540 (2*1270) patients. All patients (both cohorts) must receive dual anti-platelet therapy, being aspirin (ASA) and ticagrelor for 1 month, followed by 11 months of ticagrelor only (i.e. monotherapy). At 1 year, ticagrelor monotherapy is replaced by aspirin monotherapy or left to the discretion of the operator.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • coronary artery disease
  • ischemia
  • quantitative flow ratio (QFR)
  • P2Y12 monotherapy
  • drug-eluting stent
  • physiology guidance
  • angio-FFR
  • Coronary Angiography-derived FFR (caFFR)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has chronic stable angina, acute coronary syndromes or silent ischemia;
  • Presence of one or more coronary artery stenoses of ≥50% (by visual assessment) in a native coronary artery (with or without prior stent/other device treatment) or in a saphenous venous or arterial bypass conduit suitable for coronary stent implantation;
  • The vessel should have a reference vessel diameter of at least 2.25 mm by visual assessment (no limitation on the number of treated lesions, vessels, or lesion length);
  • Patient has been informed of the nature of the study and agrees to its provisions and has provided written as approved by the Ethical Committee and is willing to comply with all protocol-required (follow-up) evaluations.

Exclusion criteria

Exclusion Criteria:

  1. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of according to local practice);
  2. Known intolerance to cobalt chromium, and medications such as sirolimus, aspirin, heparin, bivalirudin or P2Y12 inhibitors;
  3. Planned major elective surgery requiring discontinuation of (dual)anti therapy (DAPT) within 12 months of procedure;
  4. Concurrent medical condition with a of less than 3 years;
  5. Currently participating in another trial and not yet at its primary endpoint;
  6. Active pathological bleeding;
  7. History of intracranial haemorrhage.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
2,540 participants (estimated)

Study arms

  • Other
    Angiography-derived Physiology Guidance: angio-FFR (QFR and caFFR)

    Quantitative Flow Ratio- QFR, Coronary angiography-derived FFR - caFFR

    Other: Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care

  • Other
    Local routine diagnostic procedure (LRDP) and usual care

    Other: Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care

Interventions

  • OtherAngiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care

    percutaneous coronary intervention

06

What researchers measure

Primary outcomes

  1. Patient-oriented Composite Endpoint (PoCE)

    PoCE is a composite clinical endpoint of: * all-cause death; * any stroke, Modified Rankin scale, (MRS ≥1); * any myocardial infarction; * any clinically and physiologically driven revascularization.

    Time frame: 12 months

Secondary outcomes

  1. Vessel-oriented composite endpoints (VoCE)

    VoCE is a composite clinical endpoint of: * Vessel-related cardiovascular Death * Target-vessel related MI * Clinically and physiologically-oriented Target vessel revascularization

    Time frame: 12, 24 and 36 months

  2. Device-oriented composite endpoint (DoCE)

    DoCE is a composite endpoint of: * Cardiovascular Death * Target-vessel related MI * Clinically and physiologically-oriented Target lesion revascularization

    Time frame: 12, 24 and 36 months

  3. Myocardial Infarction (MI)

    Peri-procedure Myocardial Infarction according to 4th universal definition

    Time frame: 48 hours post-procedure

  4. Device Success Rate

    according to the statement from European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology (ESC)

    Time frame: index procedure

  5. Stent Thrombosis

    Definite, Probable, Definite or Probable

    Time frame: Procedure, 12, 24 and 36 months

  6. Target Vessel Failure (TVF)

    TVF is a composite of: * Cardiovascular Death * Target-vessel related MI * Clinically and physiologically-oriented Target vessel revascularization

    Time frame: 12, 24 and 36 months

  7. Bleeding

    Bleeding according to Bleeding Academic Research Consortium (BARC) (BARC 2, 3 and 5) classification

    Time frame: 12, 24 and 36 months follow-up

07

Study locations

19 of 19 sites recruiting
  • ASZ Aalst
    Aalst, Belgium
    Recruiting
    • Liesbeth Rosseel, MD · Principal investigator
  • OLVZ Aalst
    Aalst, Belgium
    Recruiting
    • Jeroen Sonck · Principal investigator
  • Imelda Ziekenhuis
    Bonheiden, Belgium
    Recruiting
    • Kenneth De Wilder · Principal investigator
  • CHU Charleroi
    Charleroi, Belgium
    Recruiting
    • Adel Aminian · Principal investigator
  • Jessa Hospital Hasselt
    Hasselt, Belgium
    Recruiting
    • Edouard Benit · Principal investigator
  • University Hospital Galway
    Galway, Ireland
    Recruiting
    • Faisal Sharif, MD · Contact
  • OLVG Amsterdam
    Amsterdam, Netherlands
    Recruiting
    • Giovanni Amoroso · Principal investigator
  • Medisch Spectrum Twente, Thoraxcentrum, Endchede
    Enschede, Netherlands
    Recruiting
    • Clemens Von Birgelen · Principal investigator
  • UMC Groningen
    Groningen, Netherlands
    Recruiting
    • Joanna Wykrzykowska, MD PhD · Principal investigator
  • Den Haag Ziekenhuis
    Hague, Netherlands
    Recruiting
    • Samer Somi · Principal investigator
  • Medisch Centrum Leeuwarden
    Leeuwarden, Netherlands
    Recruiting
    • Sjoerd Hofma · Principal investigator
  • Maasstad Ziekenhuis
    Rotterdam, Netherlands
    Recruiting
    • Valeria Paradies · Principal investigator
  • Hospital Clínico de Barcelona
    Barcelona, Spain
    Recruiting
    • Manel Sabate · Principal investigator
  • Lucas Augusti Hospital
    Lugo, Spain
    Recruiting
    • Raymundo Ocaranza · Principal investigator
  • Hospital Clínico Universitario of Valladolid
    Valladolid, Spain
    Recruiting
    • Ignacio J Amat-Santos · Principal investigator
  • Hospital Álvaro Cunqueiro Vigo
    Vigo, Spain
    Recruiting
    • Victor Alfonso Jimenez Diaz · Principal investigator
  • Barts Health NHS Trust, London
    London, United Kingdom
    Recruiting
    • Andreas Baumbach, MD · Contact
  • Freeman Hospital
    Newcastle, United Kingdom
    Recruiting
    • Mohammad Alkhalil · Principal investigator
  • University Hospitals Southampton
    Southampton, United Kingdom
    Recruiting
    • Nick Curzen · Principal investigator
08

References and documents

Publications

  • Hara H, Serruys PW, O'Leary N, Gao C, Murray A, Breslin E, Garg S, Bureau C, Reiber JH, Barbato E, Aminian A, Janssens L, Rosseel L, Benit E, Campo G, Guiducci V, Casella G, Santarelli A, Franze A, Diaz VAJ, Iniguez A, Brugaletta S, Sabate M, Amat-Santos IJ, Amoroso G, Wykrzykowska J, von Birgelen C, Somi S, Liu T, Hofma SH, Curzen N, Trillo R, Ocaranza R, Mathur A, Smits PC, Escaned J, Baumbach A, Wijns W, Sharif F, Onuma Y; PIONEER IV trial investigator. Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design. Am Heart J. 2022 Apr;246:32-43. doi: 10.1016/j.ahj.2021.12.018. Epub 2022 Jan 3. PubMed 34990582 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Jan 2026, 50 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 50 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2021
First posted
Jun 11, 2021
StartActual
Nov 12, 2021
Primary completionEst.
Jan 2026
CompletionEst.
Jan 2029
Last update
Oct 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04923191
Lead sponsor
National University of Ireland, Galway, Ireland
Responsible party
Patrick Serruys (Professor of Interventional Cardiology & Innovation at the National University of Ireland, Galway, Ireland, National University of Ireland, Galway, Ireland) — Principal investigator
First posted
Jun 11, 2021
Start date
Nov 12, 2021
Primary completion
Jan 2026 (estimated)
Completion
Jan 2029 (estimated)
Last update
Oct 30, 2023

Study contacts

Patrick W Serruys, MD
Contact
Patrick.Serruys@universityofgalway.ie
+31622924061
Yoshinobu Onuma, MD
Contact
Yoshinobu.Onuma@universityofgalway.ie
+353852882318

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion